Silas Inman

2 weeks ago | targetedonc.com | Silas Inman

Adjuvant treatment with pembrolizumab (Keytruda) continues to demonstrate consistent benefits in both overall survival (OS) and disease-free survival (DFS) when compared to a placebo for individuals with clear cell renal cell carcinoma (ccRCC). This finding comes from a significant 5-year analysis of the phase 3 KEYNOTE-564 study, presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

2 weeks ago | curetoday.com | Silas Inman

Among patients with with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), zilovertamab vedotin, a ROR1-targeted antibody-drug conjugate, plus Rituxan (rituximab) and gemcitabine-oxaliplatin (R-GemOx) elicited an objective response rate of 56.3%, according to findings from the phase 2/3 waveLINE-003 study which were shared at the 2025 ASCO Annual Meeting.

2 weeks ago | oncnursingnews.com | Silas Inman

Zilovertamab vedotin, a ROR1-targeted antibody-drug conjugate (ADC), achieved a 56.3% objective response rate (ORR) when combined with gemcitabine-oxaliplatin (R-GemOx) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), according to data from the dose-confirmation portion of the phase 2/3 waveLINE-003 trial (NCT05139017) presented at the 2025 ASCO Annual Meeting.

3 weeks ago | cancernetwork.com | Silas Inman

In the phase 3 ANZUP 1301 trial (NCT02948543), intravesical BCG plus mitomycin showed similar efficacy and safety compared to BCG alone for patients with non–muscle-invasive bladder cancer (NMIBC), and resultedin a 40% reduction in the amount of BCG used, according to findings shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.

3 weeks ago | onclive.com | Silas Inman

The addition of the PARP inhibitor niraparib (Zejula) to abiraterone acetate (Zytiga) and prednisone (AAP) reduced the risk of radiographic progression or death by 37% compared with AAP and placebo for patients with metastatic castration-sensitive prostate cancer (mCSPC) with alterations in homologous recombination repair (HRR) genes following prior androgen deprivation therapy (ADT), according to findings from the phase 3 AMPLITUDE trial (NCT04497844) presented at the 2025 ASCO Annual...